Genmab A/S Release: Agreement for Daratumumab Receives Antitrust Clearance

Published: Sep 24, 2012

COPENHAGEN, Denmark, Sept. 21, 2012 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that the worldwide license agreement for daratumumab with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has received antitrust clearance from the Federal Trade Commission and the Antitrust Division of the Department of Justice under the Hart-Scott-Rodino Act. This means that the license agreement has now become effective. A private placement prospectus containing details of the issue of new Genmab shares to Johnson & Johnson Development Corporation in connection with the agreement has been prepared in accordance with the applicable rules and regulations and filed with the Danish Financial Supervisory Authority. Upon the agency's approval, the new Genmab shares will be registered with the Danish Business Authority by way of a capital increase in Genmab and subsequently admitted to official listing and trading on the NASDAQ OMX Copenhagen A/S, after which the subscription agreement will be considered effective. The license agreement with Janssen Biotech, Inc. was first announced on August 30, 2012 (Company Announcements 20 and 21).

Back to news